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The binding site of a novel inhibitory nanobody to GPVI has been mapped and shown to lie adjacent to 
the binding site of CRP. 
 
The structure of GPVI in complex with an inhibitory nanobody reveals a novel domain swapped 
conformation implicated in platelet signalling. 
 
Abstract 
GPVI is the major signalling receptor for collagen on platelets. We have raised 54 nanobodies (Nb), 
grouped into 33 structural classes  based on their complementary determining region 3 (CDR3) loops, 
against recombinant GPVI-Fc (dimeric GPVI) and have characterised their ability to bind recombinant 
GPVI, resting and activated platelets, and to inhibit platelet activation by collagen. Nanobodies from 
six different binding classes showed the strongest binding to recombinant GPVI-Fc suggesting that 
there was not a single dominant class. The most potent three, Nb2, 21 and 35, inhibited collagen-induced 
platelet aggregation with nanomolar IC50 values and inhibited platelet aggregation under flow. The 
binding KD of the most potent Nb, Nb2, against recombinant monomeric and dimeric GPVI was 0.6 
and 0.7 nM, respectively.  The crystal structure of monomeric GPVI in complex with Nb2 revealed a 
binding epitope adjacent to the CRP binding groove within the D1 domain. In addition, a novel 
conformation of GPVI involving a domain swap between the D2 domains was observed. The domain 
swap is facilitated by the outward extension of the C-C’ loop which forms the domain swap hinge. The 
functional significance of this conformation was tested by truncating the hinge region so that the domain 
swap cannot occur. Nb2 was still able to displace collagen and CRP binding to the mutant, but signalling 
was abolished in a cell-based NFAT-reporter assay. This demonstrates that the C-C’ loop region is 
important for GPVI signalling but not ligand binding and suggests the domain-swapped structure may 
represent an active GPVI conformation.  
 
Introduction 
The platelet glycoprotein VI (GPVI) has been identified as an attractive anti-thrombotic target 1.   GPVI 
is the major platelet signalling receptor for collagen 2, and is a receptor for other ligands, including 
fibrin 3,4. GPVI consists of two N-terminal immunoglobulin (Ig)-like domains (D1 and D2), a highly 
O-glycosylated and sialylated stalk region, a single trans-membrane spanning helix and a short 
intracellular tail 5.  There is a single N-glycosylation site in the D1 domain. GPVI signalling requires 
the FcR γ-chain homodimer, which associates through a salt bridge in the trans-membrane region of 
GPVI 6. Ligand binding occurs through the D1 domain 7,8 and leads to phosphorylation of the two 
conserved tyrosines within the immunoreceptor tyrosine based activation motif (ITAM), present on the 
FcR γ-chain, by Src family kinases 9-11. Phosphorylation of the ITAM allows the recruitment of the 
tyrosine kinase Syk via its tandem SH2 domains and further downstream signalling 12.  
GPVI has been proposed to exist as a monomer and dimer in the membrane 13-15.  The group of Moroi 
and Jung reported that recombinant dimeric GPVI, where the extracellular domains are fused to the 
dimeric Fc domain from IgG, but not monomeric GPVI, binds to collagen with micromolar affinity   16.  
They proposed that the differential binding was due either to increased avidity or to the formation of a 
dimer-specific epitope.  The latter was supported by the discovery of several dimer-specific antibodies 
that detected increased expression upon platelet activation 13-15.  Since GPVI is not present in 
intracellular stores in platelets, this suggests that the increase in binding is due to a conformational 
change as a result of dimerisation.   
The crystal structure of the recombinant GPVI extracellular domain has been solved for both unbound 
(PDB: 2GI7 and 5OU7) and collagen-related-peptide (CRP) bound forms (PDB: 5OU8 and 5OU9), 
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with both structures revealing a back-to-back dimerisation interface present within the D2 domain. 
Additionally, collagen is able to cluster GPVI receptors on the platelet membrane surface 17 and 
therefore generate higher order oligomers. GPVI-signalling occurs once a critical level of clustering has 
been reached.  The concept of a dimer-specific epitope in GPVI is not supported by the crystal structure 
of CRP-bound to GPVI which shows binding in the D1 domain and suggests a 1 : 1 stoichiometry rather 
than de novo formation of a binding epitope.  Additionally, the site of binding of the dimer-specific 
antibodies and the mechanism whereby platelet activation leads to an increase in dimerisation, are 
required to establish a full understanding of the role of dimerisation in platelet activation by GPVI. 
Nanobodies have emerged as potential therapeutic agents which have the same antigen specificity and 
binding affinity as full length antibodies but are approximately a tenth of the size.  The smaller size 
makes them more suitable to a variety of techniques including fluorescent imaging 18 as well as having 
greater tissue penetration. Nanobodies are comprised of a single variable domain derived from 
antibodies produced by camelids, which differ from human antibodies in that they do not have a light 
chain component and consist of two disulphide-linked heavy chains 19. In this report we have raised and 
characterised over 50 nanobodies against dimeric GPVI with the aim of producing a series of GPVI 
conformation-specific reagents. By solving the complex structure of GPVI with Nb2, the most potent 
GPVI inhibitory nanobody, we have revealed a novel domain swapped GPVI-dimer and mapped its 





Recombinant GPVI-Fcγ (GPVI residues1-183) was expressed in the SigpIg+ plasmid as previously 
reported 20. Nanobodies were raised against GPVI through VIB Nanobody core (VIB Nanobody 
Service Facility, Brussels, https://corefacilities.vib.be/nsf) and the DNA sequences were provided in 
PMECS vector. Goat anti-human immunoglobulin G (IgG) and rabbit anti-6-His HRP antibodies were 
purchased from ThermoFisher Scientific (Glasgow, United Kingdom) and Cambridge Bioscience 
(Cambridge, United Kingdom) respectively. Alexa Fluor-647 rabbit anti-6-His was purchased from 
ThermoFisher Scientific (Paisley, UK). Collagen was purchased from Nicomed and collagen related 
peptide (CRP) was prepared as previously described 21. CRP-XL was purchased from CAMBOL 
laboratories (Cambridge, UK). CD62P-PE and isotype IgG1 κ-PE were from Biolegend (San Diego, 
Ca, USA). PAR1 activating peptide (SFLLRN) was purchased from Severn Biotech (Kidderminster, 
UK) 
 
PCR mutagenesis  
Site-directed mutagenesis was performed on GPVI to produce the glycosylation (N72/Q), domain swap 
hinge deletion mutants and thrombin cleavable nanobodies. All mutagenesis was performed using a Q5 
site-directed mutagenesis kit (New England Biolabs) following the provided protocol. The primers used 
are shown in Supplemental Table 1.  
 
Expression and purification of recombinant GPVI 
GPVI-Fc (dimeric) was expressed and purified in the SigpIg expression vector as previously described 
20. The construct consists of both the D1 and D2 domains (residues 1-183), but does not contain the 
stalk like other GPVI-Fc constructs including Revacept 22. Monomeric GPVI was produced by cleavage 
of the Fc domain by incubating with human Factor Xa for 12-18 hours at room temperature (1 µg FXa 
for every 250 µg of GPVI) in the presence of 2.5 mM CaCl2. Protein-A chromatography was used to 
separate the cleaved Fc and GPVI followed by gel filtration using a Superdex 75 26/60. All proteins 




Expression and purification of GPVI nanobodies.  
All nanobodies were expressed in E.coli wk6 cells and contain an N-terminal PelB sequence, that allows 
for secretion of the nanobodies into the periplasmic space, and C-terminal HA and His tags. Nanobodies 
were purified using nickel affinity chromatography. For crystallography experiments, the tags were 
removed by thrombin cleavage. Detailed description of the nanobody purification is provided in the 
Supplemental methods.   
 
Solid-phase binding assay 
 
Solid-phase binding assays were performed following previously documented experimental protocols 
20. Wells were coated with collagen (4 µg/ml), CRP (4 µg/ml) or GPVI-Fc (1 µg/ml).  HRP-conjugated 
anti-Fc antibody was used for the detection of GPVI-Fc binding and HRP-conjugated anti-His was used 




Washed platelets (2x107/mL) were incubated with vehicle or PAR1 peptide (200 μM) for 3 min at room 
temp. Platelets were then incubated with each nanobodies (5 μM) and binding was detected with Alexa 
Fluor-647 rabbit anti-6-His antibody. Detailed description of the methods is provided in the 
Supplemental methods.  
 
Platelet aggregation assay 
Human platelets were freshly prepared and aggregation measured as previously described 20. Platelets 
were incubated with the nanobody for 10 min before stimulation with 5 µg/ mL collagen or 10 µg/ mL 
CRP-XL. The effect of different concentrations of the nanobody compared to PBS was determined 
using two-way ANOVA with Dunnett’s correction for multiple comparisons 
 
Whole blood microfluidics 
500 µl of whole blood was flown over Horm Collagen I (100 μg/ml) through a Maastricht parallel flow 
chamber  at a shear rate of 1000/s at room temperature as described before 23. Blood was treated with 
either PBS or nanobody (500 nM). Brightfield and fluorescence images were quantified for surface area 
coverage by specific semi-automated ImageJ scripts 24. Full methods are reported in the Supplemental 
methods.  
 
Surface plasmon resonance  
 
Surface plasmon resonance experiments were performed using a Biacore T200 instrument (GE 
Healthcare). GPVI was immobilised directly onto the CM5 chip using amine-coupling. Reference 
surfaces were blocked using 1M ethanolamine pH 8. All sensograms shown are double reference 
subtracted and at least two replicates were injected per cycle as well as experimental replicates of n=3. 
Experiments were performed at 25°C with a flow rate of 30 μL/min in HBS-EP running buffer (10 mM 
HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v surfactant P20). Each concentration of Nb2 
was run as follows; 120 sec injection, 900 sec dissociation. Kinetic analysis was performed using the 




Crystallisation and structure determination 
Crystallisation was performed using the GPVI N72Q variant and untagged Nb2. Both proteins were 
mixed at 75 µM and the complex was purified using a Superdex 200 increase 10/300 GL gel filtration 
column equilibrated in 20 mM Tris pH 7.4, 140 mM NaCl. The  complex was concentrated to 5 mg/mL. 
Crystals were generated in 0.2 M calcium acetate, 0.1M sodium cacodylate pH 6.5, 18% PEG8K and 
diffraction data was collected at the Diamond Light Source i04 beamline. 
The CCP4 software suite was used for structure determination.  Molecular replacement was performed 
in PHASER using 2GI7 and 5TP3 as templates. This was followed by model building in COOT and 
multiple rounds of refinement in REFMAC. Data collection and refinement statistics are shown in Table 
1.   
 
Nuclear factor of activated T-cell (NFAT) reporter assay  
The Nuclear factor of activated T-cell (NFAT) reporter assay was used for GPVI-signalling detection, 
following the protocol documented by Tomlinson et al. 25. DT-40 cells were transfected with 2 µg each 
of full length GPVI, FcR-γ chain and NFAT controlled luciferase reporter construct. Transfected cells 
were incubated with 100 nM of each nanobody for 15 min followed by stimulation upon the addition 
of 10 µg/mL collagen or CRP. All readouts were expressed as a percentage of the signal from collagen 
alone. GPVI surface expression was confirmed by cell labelling samples with HY101 antibody followed 
by anti-mouse Alexa Fluor-647 secondary antibody staining and performing flow cytometry. The 




Results are shown as mean values ± standard deviation. ELISA assays were performed with n=3 
whereas NFAT assays were performed with n= 5. Student two-tailed t test was used and P < 0.05 taken 




Testing of nanobodies on recombinant GPVI 
The recombinant GPVI used for immunisation and testing consisted of the extracellular D1 and D2 
domains fused with the Fc domain from IgG. Immunisation with GPVI-Fc yielded 54 distinct nanobody 
sequences. The Fc domain was used to test whether the nanobodies recognise this region. The 54 
nanobodies were categorized into 33 distinct binding classes on the basis of their complementary 
determining region 3 (CDR3) sequence, which is the region that confers ligand specificity26. 
Nanobodies with CDR3 regions with >80 % homology were considered to be in the same binding class. 
Nanobodies (1 µM) from each binding class were tested for their ability to recognise a recombinant 
GPVI-Fc coated surface (Figure 1a). The degree of nanobody binding varied between classes and could 
be categorised into strong (>50 %), moderate (>20 %) and weak binders (<20 %).  Strong binders 
included Nb2, 21, 35 and 52. Moderate binders included Nb7, 18, 28 and 54. All other nanobodies were 
considered to be weak binders.  
We used a nuclear factor of activated T-cells (NFAT) reporter assay to investigate GPVI signalling in 
a transfected cell line (Figure 1b). This assay takes advantage of  ITAM signalling through Src and Syk 
tyrosine kinases which results in NFAT-dependent expression of a luciferase reporter 25. Collagen 
stimulated an 8.3 + 2.8 fold increase in NFAT activity. Nbs 2, 21 and 35 (100 nM) inhibited the increase 
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by greater than 80 %, and Nbs 5, 22, 25 and 44 inhibited this by more than 50 %. Several nanobodies, 
Nbs 6, 24, 28-30 and 49, increased the response to collagen and the remainder either had no effect or 
resulted in inhibition < 50 %. The marked potency of Nbs 2, 21 and 35 is in line with their high affinity 
for binding to GPVI (Figure 1a). 
 
Evaluation of Nbs 2, 21 and 35 as blocking agents 
 
The most potent nanobodies, Nb2, 21 and 35, were further tested in their ability to inhibit GPVI 
function. Firstly, their binding toplatelets was tested using flow cytometry. All three nanobodies 
exhibited similar binding to resting and activated platelets in the presence of PAR1 activating peptide 
(200 μM) (Figure 2a) suggesting that they recognise both monomeric and dimeric GPVI. Previously, 
Jung et al 14 have reported that thrombin stimulates dimerisation of GPVI.Further studies were 
performed on these nanobodies to investigate the concentration response relationship in binding to 
GPVI and for inhibition of platelet aggregation and adhesion under flow. Nbs 2, 21 and 35 inhibited 
platelet aggregation to collagen (5 g/mL and CRP (10 g/ml) with IC50 values of 172, 85 and 115 nM 
for collagen, and 1, 22 and 1 nM for CRP, respectively (Figure 2b). The differential IC50 values is 
likely to reflect binding of collagen to a second receptor on platelets, integrin 21. 
In a solid-phase binding assay, all three nanobodies blocked the binding of GPVI-Fc (100 nM) to a 
collagen surface with IC50 values for Nbs 2, 21 and 35 of 18, 61 and 39 nM, respectively (Figure 2c). 
The binding affinity of the most potent of the three nanobodies, Nb2, to immobilised GPVI and GPVI-
Fc was determined by SPR with a calculated equilibrium dissociation constant (KD) of 0.7 nM ± 0.03 
nM and 0.58 nM ± 0.06 nM for GPVI-Fc and GPVI respectively (Figure 2d-e). This binding affinity is 
approximately 25-fold higher than that of the full-length inhibitory GPVI antibody 9012 27.  The similar 
binding affinities to monomeric and dimeric GPVI is consistent with the observation that binding of 
Nb2 to platelets is not altered upon thrombin stimulation.To assess the effect of the most potent anti-
GPVI nanobodies on platelet activation and subsequent thrombus formation a whole blood flow 
adhesion assay was performed. Blood from healthy donors was preincubated with either PBS or 500 
nM Nb2, 21 or 35 for 10 minutes, thrombin inhibited, recalcified and then flown over collagen at a 
shear rate of 1000/s. Quantitative analysis of the images demonstrated that all three Nbs had no 
significant effect on platelet adhesion under flow (Figure 3b), but that they inhibited the formation of 
multilayered aggregates (Figure 3c). The platelets that did adhere also had abrogated PS-exposure 
relative to  untreated controls (Figure 3d). The abolition of aggregation and PS exposure, but not 
adhesion, is consistent with results in GPVI-deficient patients 23. 
 
Nb2 binds close to the CRP binding epitope and reveals a novel domain-swapped dimeric GPVI 
structure 
 
We next aimed to solve the crystal structure of the most potent of the Nbs, Nb2, with recombinant 
GPVI. Crystallisation of dimeric GPVI-Fc was not successful so monomeric GPVI was used. For these 
studies, the single N-glycosylation site at N72 was mutated to glutamine (GPVI NQ). GPVI NQ was 
mixed with Nb2 in a 1:1 ratio at a concentration of 75 M and purified as a complex by gel filtration 
(Supplemental Figure 4).The crystal structure of this complex was solved with a resolution of 2.2 Å. 
The structure revealed the binding epitope of Nb2 and a novel GPVI dimer conformation (Figure 4). 
The dimer interface consisted of two domain-swapped D2 domains formed through the extension of the 
C-C’ loop region (labelling in accordance with Horii et al. 28). This extended loop forms a domain swap 
hinge that extends outwards and folds with an adjacent D2 (Figure 4b). This is in stark contrast with the 
back to back D2 dimer reported in previous crystal structures 28. Additional novel features within the 
D2 structure are shown in Figure 4b-c. No observed electron density was found between residues K135-
R142, which in previous structures forms the C-terminal end of the C-C’ hinge loop and the start of the 
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C’ β-strand. In addition, there is a slight shift within the E β-strand, which in previous structures is made 
up of residues I147-V150 but is formed by residues S144-I148 in the domain swapped structure. The 
loop between the E and F β-strands forms a short 310 helix which has not been observed in other D2 
structures but is present within D1. These small structural changes are likely the result of the extension 
of the hinge loop towards the adjacent subunit and subsequent destabilisation of the C’ β-strand. 
The Nb2 binding site was mapped within D1 adjacent to the CRP binding site. Residues involved in the 
Nb2-GPVI binding interface are shown in Figure 5a. The primary interaction interface is found towards 
the top of the CRP binding groove within the D1 C’ β-sheet and 310 helix found between βE and F 
strands. This forms a primary binding pocket and polar contacts between nanobody residues within the 
CDR3 loop with GPVI residues S45-Y47 found within the D1 C’ β-sheet, and S61 found in the short 
310 helix. Additional contacts within the primary binding site are made between Nb2 CDR1 residue Y31 
and GPVI residue Q48. A secondary interaction pocket is located away from the CRP binding groove 
made by residues Q1 and Y115 of Nb2 interacting with E21, P56 and A57 of GPVI. A summary of 
binding residues is presented in Supplemental Table 2. The GPVI binding site lies entirely within the 
CDR3 loop of Nb2 apart from Q1 and Y31. The Nb2 binding site is adjacent to the CRP binding 
interface (Figure 5b) with the CDR2 loop extending towards the CRP binding site which would induce 
steric clashes between both ligands. In addition, the binding of the CDR3 loop to the short C’ β-sheet 
of D1 the top of the CRP binding groove induces a small shift of approximately 1.5 Å which causes a 
small distortion of the groove (Figure 5b).  A Ca2+ cation can be found bridging two Nb2 subunits, 
through interactions with the side chain carboxyl group of E6 and peptide backbone carbonyl of G119,  
and two water molecules resulting in an octahedral Ca2+ ion coordination.  In summary, the 
crystallisation of the GPVI-Nb2 complex has revealed that the Nb2 binding site lies in close proximity 
to the CRP binding site and induces a small conformational change in D1. The structure also reveals a 
domain swap between the D2 domains.   
 
Truncating the domain swap hinge region prevents GPVI-signalling but not ligand binding 
The domain-swapped structure shows a critical role for the C-C’ hinge region which, in the original 
structure of GPVI, was modelled as an unstructured loop region in one of the two GPVI monomers and 
was not resolved in the other. In a more recent crystal structure of the GPVI dimer in complex with 
CRP, this hinge region was removed which means that the domain swap would not have been possible, 
and the structure of GPVI was the same as the original structure (PDB ID: 5OU7). The position of the 
hinge region in the nanobody bound structure and original GPVI structure is shown in Figure 6a. 
Since the hinge truncated variant of GPVI is still able to bind CRP, as shown in the crystal structure, 
this provides a mechanism of testing the functional significance of the domain swapped structure. We 
therefore utilised site directed mutagenesis to truncate the length of hinge region (amino acids 
G129DPAPYKN136) and prevent formation of the domain swapped dimer configuration both in a 
recombinant GPVI construct and in full length GPVI (named ΔC-C’). A solid-phase binding assay 
showed that GPVI-Fc ΔC-C’ bound to both collagen- and CRP-coated surfaces in a concentration 
dependent manner. Calculated EC50 values for binding to collagen were 294 nM compared with 42 nM 
for GPVI-Fc and 9 nM compared to 2 nM for GPVI-Fc binding to CRP (Figure 6b i). Nb2 showed an 
increased potency for displacement of the interaction of GPVI-Fc ΔC-C’ to collagen and CRP with an 
IC50 of 51 and 17 nM respectively, compared with 268 and 132 nM for GPVI-Fc WT (Figure 6b ii), 
reflecting the lower affinity of collagen and CRP for the mutant. This suggests that the collagen and 
CRP binding site has undergone a small conformational change that results in reduced ligand binding. 
Nb2 binding to this mutant was comparable to GPVI-Fc with a KD of 2.6 nM ± 0.4 nM as determined 
by SPR (Supplemental Figure 6) .  Interestingly collagen and CRP were unable to activate full-length 
GPVI ΔC-C’ construct expressed in a cell line using the NFAT reporter assay (Figure 6c). These results 
provide evidence that the hinge region may be required for maintaining the conformation of the ligand 





In this study we have developed a range of nanobodies to GPVI and characterised these using a variety 
of assays. These studies show the following: (i) a diverse range of nanobodies with sequence differences 
in their CDR3 domains bind to GPVI; (ii) the most potent of these, Nb2, 21 and 35, bind with nanomolar 
affinity and block collagen-induced NFAT activation, platelet aggregation and thrombus formation 
under flow; (iii) a crystal structure reveals Nb2 binds to a site on GPVI which is adjacent to the CRP 
binding site; and (iv) Nb2 forms a complex with a novel domain-swapped GPVI dimer. Together, the 
nanobodies form a library of agents for probing GPVI function in platelets. It should be noted that all 
nanobodies excluding Nbs 6, 11 and 53, were directly displaced by Nb2 in a competition ELISA (data 
not shown) which suggests most of the nanobodies may bind close to the Nb2 binding site on D1.  
 
The presence of a domain-swapped GPVI-dimer offers a new scaffold to examine GPVI dimerisation. 
A critical feature of the domain swap is the extension of the C-C’ hinge. The construct used to solve 
the complex crystal structure with CRP was also missing the C-C’ hinged loop region and so a domain 
swapped dimer could not be formed. The construct used by Horii et al. for the original GPVI crystal 
structure did include the hinge loop but the domain swap was not observed, and the back to back dimer 
conformation was instead reported. The different conformations between the Horii et al. structure and 
the domain-swapped structure we describe here could be due to the different crystallisation conditions 
utilised between experiments. A second explanation is that the nanobody stabilises the domain swapped 
conformation in the crystal and represents just one potential dimeric conformation adopted by GPVI. 
Dimerisation of recombinant D1,D2 has not been detected in solution 28 and the formation of stable 
dimers likely requires additional contact regions such as the disulphide formed within the intracellular 
tail 29.  
By producing a GPVI deletion mutant with a shortened hinge region we have attempted to address the 
functional significance of the domain-swapped GPVI conformation. In the original non-domain 
swapped structure (PDB:2GI7), the C-C’ loop does not form a domain swap hinge but forms a 
disordered loop that points away from the rest of the protein (Figure 5b), therefore, shortening this loop 
would not have a significant impact on GPVI structure unless a domain swap is formed. This is 
supported by a previously solved structure of GPVI without the C-C’ loop (PDB:5OU7) that shows no 
significant conformational changes within D1 or D2 compared with the original structure. Strikingly, 
collagen and CRP were unable to activate the hinge mutant which, although not direct evidence for the 
presence of a domain-swap, does suggests that the domain swap may be important for GPVI signalling. 
Although binding to CRP and collagen is slightly reduced in the mutant, binding still occurs and the 
reduction in binding affinity would not result in complete abolition of signalling. However, these results 
do not definitively prove the existence of a domain-swap. The hinge region may have alternative 
functions such as being an allosteric modulator of GPVI upon ligand binding. The inability to detect 
recombinant GPVI dimers in solution is a limiting factor for this study, and other cell line techniques 
such as nanoBRET 30 would need to be performed to confirm the role of the hinge region in GPVI 
dimerisation.  
The crystal structure of Nb2 bound GPVI reveals that Nb2 interacts with the top of the CRP binding 
groove and, although not directly overlapping with the CRP binding site, is close enough to sterically 
hinder the binding to collagen. Inhibition of collagen binding by Nb2 is likely however a combination 
of steric clashes between closely positioned binding sites as well as the distortion of the CRP binding 
groove, shown in Figure 5c, indicative of a mixed mode allosteric and competitive inhibitor. Nb2 
therefore provides a new scaffold that can be used for the development of anti-thrombotic drugs to treat 
cardiovascular disease.  
In summary, our results provide evidence that GPVI signalling requires an active domain swapped 
conformation of GPVI and offers a new mechanistic insight into GPVI activation. Full-length structures 
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of GPVI in both resting and activated states are required to confirm the role of the domain-swapped 
conformation in GPVI activation.  
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Data collection Value 
Space group P 21 21 21 
Cell dimensions 
a, b, c (Å) 
α, β, γ (°) 
 
69.91   84.75  124.04   
 90.00   90.00   90.00 
Resolution (Å) 84.57– 2.5 
R merge  0.122 (0.595)* 
I/ σI 8.67 (2.69)* 
Completeness (%) 100 (98.6)* 
Redundancy 6.3 (6.4)* 
Wavelength 0.96864 Å 
Refinement  
No of reflections 26173 
Rworkb / R free (%) 0.176 / 0.232 








R.m.s deviations  
Bond lengths (Å) 0.0084 
Bond angles (°) 1.568 
Table 1: Crystallographic data collection and refinement statistics. 
*Values in parentheses are for highest-resolution shell. 
aRmerge = Σh Σi| <Ih> - Ih,i|/Σh Σi Ih,I where I is the observed intensity and <Ih> is the average 
intensity of multiple observations from symmetry-related reflections calculated.  
 bRwork = Sum(h) ||Fo|h - |Fc|h| / Sum(h)|Fo|h, where Fo and Fc are the observed and 
calculatedstructure factors, respectively. Rfree computed as in Rwork, but only for (5%) randomly 

















Figure 1.  Testing of nanobody binding and inhibition of GPVI signalling. a) Surface binding 
assay of one nanobody (100 nM) from each binding class to a GPVI-Fc coated-surface. All the 
binding results have been normalised to Nb35 which gave the highest readout. Binding of each 
nanobody to the Fc domain-coated surface was tested and subtracted from the GPVI-Fc readings. 
Binding was detected using HRP conjugated anti-His antibody. The average binding of all the 
nanobodies to BSA represents a non-specific binding control. Data represent mean values of three 
experiments ± standard deviation. b) NFAT reporter assay of GPVI and FcRγ transfected DT40 cells 
stimulated by collagen (10 µg/ml) in the presence of the nanobodies (100 nM). Results were plotted 
as a percentage of total signalling in the presence of collagen only. Dotted lines represent 100, 50 and 
20 % signalling levels and nb2, 21 and 35 are coloured in black, red and orange respectively. Data 




Figure 2.  Further testing of top inhibitory nanobodies of GPVI. a) Nanobodies 2, 21 and 35 (5 
µM) binding to washed platelets in the presence or absence of 200 μM PAR1 by flow cytometry. 
Grey histograms show unstained washed platelets, black histograms show non-specific staining of 
anti-his alexafluor647 secondary, red histograms show nanobody binding to resting platelets and 
green histograms show nanobody binding to PAR1 peptide-activated platelets. b) Platelet aggregation 
in response to i) 5 µg/mL collagen and ii) 10 µg/mL CRP in the presence of Nb2, 21 and 35. Top 
panel shows representative aggregation curves for Nb2 whereas the bottom panel shows max 
aggregation values for all nanobodies. IC50 values of 172, 85 and 115 nM for collagen and 1, 22 and 
1 nM for CRP were determined for Nb2, 21 and 35, respectively. The effect of different 
concentrations of the nanobody compared to the vehicle (PBS) was determined using two-way 
ANOVA with Dunnett’s correction for multiple comparisons. c) Solid-phase binding assay showing 
GPVI-Fc (100 nM) displacement from a collagen surface in the presence of increasing concentration 
Nb2, 21 and 35, with IC50 values of 18, 62 and 39 nM respectively. Data represent mean values of 
three ± standard deviation. d-e) SPR data showing Nb2 at a range of concentrations binding to GPVI-
Fc (d) and GPVI (e) immobilised on a surface. The binding affinity was determined by kinetic 






Figure 3. Effect of anti-GPVI nanobodies in whole blood microfluidics. a) Representative images 
of whole blood perfused at an arterial shear rate (1000/s) over Horm Collagen I in the presence of 
either PBS, 500 nM nanobody 2, 21 or 35. Adhered platelets and platelet aggregates were imaged in 
brightfield after 3.5 minutes of flow. Platelets were labeled with Annexin V AF568 to assess 
phosphatidylserine (PS) exposure. All images were taken on an EVOS AMF4300 using a 60x, 
1.42NA oil objective. Data are representative of 2 runs for each of 3 donors per treatment. Scale bar: 
50 µm. Quantitative analysis of the images assessed the effect of the nanobodies on percentage of 
total surface area covered by b) platelets, c) multilayered thrombi and d) platelets exposing PS. Data 
points are individual runs for each of 3 donors (shown in different colours) per treatment (Mean ±SD). 
Unpaired t-test with Mann Whitney correction was employed to test for statistical significance,  




Figure 4. Crystallisation of Nb2 and GPVI. a) Structure of Nb2 binding to GPVI. (i) A side view of 
the GPVI-Nb2 structure; (ii) A top down view illustrating the domain swap hinge region. A cartoon 
representation is shown below each figure.  Separate GPVI protein subunits are shown in green and 
cyan, and both Nb2 proteins are shown in yellow and pink. The domain-swapped D2 domains are 
labelled D2a and D2b for the N and C-terminal D2 regions respectively. b) Comparison of the D2 
domains from the non-domain swapped structure (PDB: 2GI7) (bi) and the domain swapped structure 
(bii) with major features highlighted. This highlights the differences within the C-C’ hinge region, the 
C’ β-strand where no electron density was observed for the domain swapped structure and the 
presence of an 310 helix  between β E and F. c) Zoomed in view of the D2 domain swap hinge region 
with the hinge loops coloured in green and cyan and the inter-chain polar contacts, which stabilise this 
region, shown as red dashes.  
 
 
Figure 5.  Site of interaction of GPVI with Nb2 and CRP. a) Zoomed in view of the GPVI : Nb2 
binding interface. GPVI is coloured in light green, and Nb2 binding residues in the CDR3 loop are 
coloured in blue and non-CDR3 residues in pink. Red dashed lines indicate polar contacts made 
between GPVI and Nb2 residues. The full CDR3 sequence for Nb2 is provided underneath the 
structure with binding residues highlighted in bold. b) Zoomed in view of the CRP binding groove of 
the CRP bound GPVI structure (pink) and nanobody bound structure (green), with CRP shown in 
cyan and Nb2 cdr3 residues 100-105 shown in blue. The binding of Nb2 towards the top of the 
binding groove results in a shift of the βC’ sheet resulting in a small distortion of the CRP binding 
groove. c) Locations of the known Nb2 and CRP binding sites on GPVI. i) Surface representation of 
Nb2 (pink) modelled onto the GPVI-CRP complex structure (PDB:  5OU8), coloured in green and 
cyan respectively, revealing the two non-overlapping but closely situated binding sites. ii) Nb2 and 
CRP binding residues mapped as pink and cyan spheres respectively on the structure of GPVI. 
 
Figure 6. The domain swap is required for signalling but not ligand binding. Ai and ii) Crystal 
structures of the nanobody bound and original unbound GPVI structures respectively, highlighting the 
region of the C-C’ hinge loop (coloured in orange) deleted for mutation studies. The domain swapped 
structure contains two GPVI subunits coloured in green and cyan whereas only one subunit is shown 
for the original GPVI structure. The domain-swapped D2 domain is labelled D2a and D2b for the N 
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and C-terminal D2 regions respectively.  bi) Solid-phase binding assay comparing the dose-dependent 
binding of GPVI-Fc and GPVI-Fc ΔC-C’ to collagen and CRP coated surface. Respective EC50 
values of 42 and 294 nM were calculated for GPVI and GPVI ΔC-C’ binding to collagen and 2 and 9 
nM for CRP.  ii) The binding of GPVI-Fc and GPVI-Fc ΔC-C’ to a collagen and CRP-coated surface 
and subsequent displacement by increased concentrations of Nb2. 500 nM GPVI was used for 
collagen and 100 nM GPVI was used for CRP. Data has been normalised against the highest and 
lowest concentrations of Nb2 and is expressed as % binding. Respective IC50 values of 268 and 51 
nM were calculated for GPVI and GPVI ΔC-C’ binding to collagen and 132 and 17 nM for CRP. Data 
represent mean values of three experiments ± standard deviation. c) NFAT-reporter assay of DT40 
cells transfected with the FcR-γ chain and either full length GPVI WT or hinge mutant. Luciferase 
activity was reported for non-stimulated, CRP and collagen stimulated cells. Data represent mean 
values of five experiments performed in triplicate ± standard deviation and values are normalised 
against the respective basal levels. A student two-tailed t test was used to determine significance 
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